Jan Madison, MD
Pulmonary Disease · Rostraver Township, PANPI 1275529760
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.4%), food and beverage and education — rather than concentrated in one kind of arrangement. GSK accounts for 60.5% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2020 at $9,528 and has fallen 80.7% since, to $1,836 in 2025. Among pulmonary disease clinicians in PA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $52.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$11K
- AstraZeneca$2K
- Sanofi$829
- Regeneron Healthcare Solutions, Inc.$495
- Grifols USA, LLC$447
- Boehringer Ingelheim$441
- plus $3K from 26 others
Across 15 payments — averaging $1378.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$11K
- AstraZeneca$6K
- GSK$3K
What the payments were for
- Consulting fees$9,42551%
- Food & beverage$8,60247%
- Education$3162%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 88 | $11,089 |
| AstraZeneca | 75 | $2,434 |
| Sanofi | 20 | $829 |
| Regeneron Healthcare Solutions, Inc. | 12 | $495 |
| Grifols USA, LLC | 19 | $447 |
| Boehringer Ingelheim | 26 | $441 |
| Amgen | 16 | $394 |
| Novartis | 10 | $367 |
| Philips North America LLC | 17 | $299 |
| Electromed, Inc. | 14 | $207 |
| Genentech USA, Inc. | 5 | $198 |
| Pfizer | 2 | $130 |
| Harmony Biosciences LLC | 5 | $125 |
| Insmed, Inc. | 7 | $117 |
| Inspire Medical Systems, Inc. | 1 | $109 |
| Merck | 6 | $101 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| United Therapeutics Corporation | 3 | $72 |
| Shire North American Group Inc | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Gilead | 3 | $38 |
| Baxter Healthcare | 2 | $38 |
| Verona Pharma, Inc. | 2 | $38 |
| Inogen, Inc. | 2 | $35 |
| Grifols Shared Services North America, Inc. | 1 | $30 |
| Mallinckrodt Hospital Products Inc. | 2 | $30 |
| Vifor Pharma, Inc. | 1 | $23 |
| Vapotherm Inc | 1 | $20 |
| Advanced Respiratory, Inc | 1 | $17 |
| CSL Behring | 1 | $16 |
| Pulmonx Corporation | 1 | $15 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TRELEGY ELLIPTA$4,021
- DUPIXENT$597
- TEZSPIRE$357
- FASENRA$229
- NUCALA$221
- XOLAIR$122
- AIRSUPRA$121
- Prolastin-C Liquid$120
- AREXVY$115
- Inspire Upper Airway Stimulation System$109
- Prolastin-C$107
- BREZTRI$104
How this compares
$18,343 in reported general payments places this provider in the 90th percentile of 703 pulmonary disease providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 256 | $213,646 |
| TezspireTezepelumab-Ekko | 33 | $158,617 |
| NucalaMepolizumab | 14 | $51,498 |
| Breo ElliptaFluticasone/Vilanterol | 59 | $27,361 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 20 | $12,840 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 16 | $10,958 |
| Advair HfaFluticasone Propion/Salmeterol | 14 | $5,051 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 117 | $4,135 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $3,140 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 15 | $3,063 |
| Montelukast Sodium | 289 | $2,849 |
| Advair DiskusFluticasone Propion/Salmeterol | 11 | $2,029 |
| Theophylline ErTheophylline Anhydrous | 19 | $1,559 |
| Ventolin HfaAlbuterol Sulfate | 16 | $1,131 |
| Prednisone | 199 | $1,010 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta | $11,089 | $303,462345 claims |
| AstraZenecaTezspire, Breztri Aerosphere | $2,434 | $171,45753 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 703 pulmonary disease providers in Pennsylvania.
Other pulmonary disease in Rostraver Township
- Sandeep Bansaldu Bois$1.4M
- Alan KanouffAltoona$809K
- Gerard CrinerPhiladelphia$657K
- Kenneth LanderUpland$647K
- Richard FriedenheimAbington$627K
- Thomas MeyerWynnewood$615K
- Surya BhattBethlehem$579K
- Tariq CheemaPittsburgh$549K
- Stephen KovacsErie$520K
- Michael ZlupkoAltoona$468K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.